Table 1.

Impact of different PRT on overall immunoglobulin levels and/or anti-SARS-CoV-2 neutralizing antibodies.

PRT brand	PRT effect on IgG or nAb levels	# of treated plasma units	Ref
Intercept®	No significative difference in EBOV nAb titer	10	[37]
	−2% to −4% EBOV IgG	1	[38]
	No significative difference in SARS-CoV-2 nAb titer	5	[25]
	−3.8% anti-SARS-CoV-2 N protein IgG	48	[39]
	No difference in SARS-CoV-2 nAb titer and N-protein antibodies	110	[26]
	No significative difference in SARS-CoV-2 nAb titer	30	[27]
	Among units with the initial SARS-CoV-2 nAb titre ≥ 80: 60% (47%–73%, CI) were unchanged 40% decreased by one dilution	140	[28]
Mirasol®	−13% to −22% total IgG after 69 week storage at −30 °C	6	[40]
	−17.1% total IgG and −23.6% IgG1 (significant)	6	[29]
	−16.6% total IgG and −32.3% IgG1 (significant), but no significant difference in Tetanus, Diphteria and Pneumococcal protective antibody titers	6	[30]
	−12.7% anti-SARS-CoV-2 N-protein IgG	20	[39]
	Among units with the initial SARS-CoV-2 nAb titre ≥ 80: 43% (26%–61%, CI) were unchanged 50% had a one-dilution decrease 7% had a two-dilution decrease	140	[28]
Theraflex MB®	−4.8% anti-SARS-CoV-2 N-protein IgG	22	[39]
	Among units with the initial SARS-CoV-2 nAb titre ≥ 80: 81% (71%–91%, CI) of units remained unchanged 19% decreased by one dilution	1401	[28]